Literature DB >> 26823763

Development of an improved animal model of experimental autoimmune myositis.

Juan Kang1, Hong-Ya Zhang1, Guo-Dong Feng1, Dong-Yun Feng1, Hong-Ge Jia1.   

Abstract

Multiple animal models of experimental autoimmune myositis (EAM) have been developed. However, these models vary greatly in the severity of disease and reproducibility. The goal of this study was to test whether vaccination twice with increased dose of rat myosin and pertussis toxin (PT) could induce EAM with severer disease in mice. BALB/c mice were injected with 1 mg rat myosin in 50% complete Freund's adjuvant (CFA) weekly for four times and one time of PT (EAM) or twice with 1.5 mg myosin in CFA and PT (M-EAM). In comparison with that in the CFA and PT injected controls, vaccination with rat myosin and injection PT significantly reduced the muscle strength and EMG duration, elevated serum creatine kinase levels, promoted inflammatory infiltration in the muscle tissues, leading to pathological changes in the muscle tissues, demonstrating to induce EAM. Interestingly, we found that vaccination twice with the high dose of myosin and PT prevented EAM-related gain in body weights and caused significantly less muscle strength in mice. More importantly, all of the mice receiving high dose of myosin and PT survived while 3 out of 16 mice with four times of low dose of myosin died. Finally, vaccination with high dose of myosin promoted CD4(+) and CD8(+) T cell infiltration in the muscle tissues and up-regulated MHC-I expression in the muscle tissues of mice. Hence, the new model of EAM is a time-saving, efficient and easily replicable tool for studying autoimmune myositis.

Entities:  

Keywords:  Experimental autoimmune myositis (EAM); animal models; idiopathic inflammatory myopathies (IIM); immunosuppressive

Mesh:

Substances:

Year:  2015        PMID: 26823763      PMCID: PMC4713549     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

Review 1.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

Review 2.  Immunosuppressant and immunomodulatory treatment for dermatomyositis and polymyositis.

Authors:  Patrick A Gordon; John B Winer; Jessica E Hoogendijk; Ernest H S Choy
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

3.  A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice.

Authors:  C Contet; J N Rawlins; R M Deacon
Journal:  Behav Brain Res       Date:  2001-09-28       Impact factor: 3.332

4.  Experimental myositis inducible with transfer of dendritic cells presenting a skeletal muscle C protein-derived CD8 epitope peptide.

Authors:  Naoko Okiyama; Hisanori Hasegawa; Takatoku Oida; Shinya Hirata; Hiroo Yokozeki; Manabu Fujimoto; Nobuyuki Miyasaka; Hitoshi Kohsaka
Journal:  Int Immunol       Date:  2015-01-10       Impact factor: 4.823

Review 5.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

6.  Pulse Dose Methylprednisolone Therapy for Adult Idiopathic Inflammatory Myopathy.

Authors:  Padmanabhan Raghu; Augustine M Manadan; Juan Schmukler; Tanisha Mathur; Joel A Block
Journal:  Am J Ther       Date:  2015 Jul-Aug       Impact factor: 2.688

7.  Characterization of pathogenic T cells and autoantibodies in C-protein-induced autoimmune polymyositis.

Authors:  Yoh Matsumoto; Kuniko Kohyama; Il-Kwon Park; Mie Nakajima; Keiko Hiraki
Journal:  J Neuroimmunol       Date:  2007-09-27       Impact factor: 3.478

8.  Notch1 and TGFbeta1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells.

Authors:  Jeremy B Samon; Ameya Champhekar; Lisa M Minter; Janice C Telfer; Lucio Miele; Abdul Fauq; Pritam Das; Todd E Golde; Barbara A Osborne
Journal:  Blood       Date:  2008-06-11       Impact factor: 22.113

Review 9.  Role of cytokines and chemokines in idiopathic inflammatory myopathies.

Authors:  Boel De Paepe; Kim K Creus; Jan L De Bleecker
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

10.  The injury-induced myokine insulin-like 6 is protective in experimental autoimmune myositis.

Authors:  Ling Zeng; Sonomi Maruyama; Kazuto Nakamura; Jennifer L Parker-Duffen; Ibrahim M Adham; Xuemei Zhong; Han-Kyu Lee; Henry Querfurth; Kenneth Walsh
Journal:  Skelet Muscle       Date:  2014-08-04       Impact factor: 4.912

View more
  6 in total

1.  Knockdown of lncRNA HAGLR promotes Treg cell differentiation through increasing the RUNX3 level in dermatomyositis.

Authors:  Wang Yan; Lulu Wang; Zhaoying Chen; Chengyao Gu; Caijing Chen; Xiaoxia Liu; Qin Ye
Journal:  J Mol Histol       Date:  2022-01-22       Impact factor: 2.611

2.  Toll-Like Receptor 4-Myeloid Differentiation Primary Response Gene 88 Pathway Is Involved in the Inflammatory Development of Polymyositis by Mediating Interferon-γ and Interleukin-17A in Humans and Experimental Autoimmune Myositis Mouse Model.

Authors:  Hongya Zhang; Fangyuan He; Ming Shi; Wenxiu Wang; Xiaojia Tian; Juan Kang; Wenjuan Han; Rui Wu; Linfu Zhou; Mengmeng Hu; Xiaobo Li; Fang Mi; Gang Zhao; Hongge Jia
Journal:  Front Neurol       Date:  2017-04-12       Impact factor: 4.003

3.  Expression of a constitutively active human STING mutant in hematopoietic cells produces an Ifnar1-dependent vasculopathy in mice.

Authors:  Gary R Martin; Kimiora Henare; Carolina Salazar; Teresa Scheidl-Yee; Laura J Eggen; Pankaj P Tailor; Jung Hwan Kim; John Podstawka; Marvin J Fritzler; Margaret M Kelly; Bryan G Yipp; Frank R Jirik
Journal:  Life Sci Alliance       Date:  2019-06-20

4.  A novel model of dermatomyositis induced by membrane antigen and calciphylaxis in rats.

Authors:  Xin Zhao; Lingyu Li; Shasha Ge; Jinyu Liu; Shuang Li; Hongya Wang; Dayong Cai
Journal:  Biomed Rep       Date:  2022-02-24

5.  Comparison of rapamycin and methylprednisolone for treating inflammatory muscle disease in a murine model of experimental autoimmune myositis.

Authors:  Juan Kang; Dongyun Feng; Feng Yang; Xiaojia Tian; Wenjuan Han; Hongge Jia
Journal:  Exp Ther Med       Date:  2020-05-05       Impact factor: 2.447

6.  Reduced miR-146a Promotes REG3A Expression and Macrophage Migration in Polymyositis and Dermatomyositis.

Authors:  Tingwang Jiang; Yuanlan Huang; Haohao Liu; Qiangwei Xu; Yanping Gong; Yao Chen; Xiaowei Hu; Zhijun Han; Mingzhu Gao
Journal:  Front Immunol       Date:  2020-02-21       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.